Sergei Gryaznov

Department of Biotechnology — India

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index6.0kcitations173works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced biosensing and bioanalysis techniques(78), Telomeres, Telomerase, and Senescence(77), RNA Interference and Gene Delivery(59), DNA and Nucleic Acid Chemistry(58), RNA and protein synthesis mechanisms(28)

Publications173 total

564 A phase 2 study of ateganosine (THIO) in combination with immune checkpoint inhibitor (ICI) in patients with advanced NSCLC resistant to prior ICI and chemotherapy: THIO-101 trial in progress
Regular and Young Investigator Award Abstracts·2025Open Access
563 A phase 3 study of ateganosine (THIO) sequenced with immune checkpoint inhibitor (ICI) versus standard of care chemotherapy in ICI-resistant advanced NSCLC: THIO-104 trial in progress
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract B015: A Phase 2 Study of Ateganosine (THIO) in Combination with Immune Checkpoint Inhibitor (ICI) in Patients with Advanced NSCLC Resistant to Prior ICI and Chemotherapy: THIO-101 Trial in Progress
Molecular Cancer Therapeutics·2025
Novel telomere-targeting dual-pharmacophore dinucleotide prodrugs for anticancer therapy
Nucleic Acids Research·2025· 1 citedOpen Access
Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor–resistant advanced NSCLC: Evaluation of overall survival (OS).
Journal of Clinical Oncology·2025
1492 Telomere-targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic benefits beyond treatment cessation – A phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients
2024· 1 citedOpen Access
A Phosphatidyl Conjugated Telomerase-Dependent Telomere-Targeting Nucleoside Demonstrates Colorectal Cancer Direct Killing and Immune Signaling
Preprints.org·2024Open Access
A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results.
Journal of Clinical Oncology·2024· 1 cited
Abstract 5108: Immunomodulatory and anti-tumor effect of radiation and induced telomere damage to treat pediatric high-grade gliomas
Cancer Research·2024
Retraction: Effects of Oligonucleotide N3′→P5′ Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells
Cancer Research·2024Open Access
1493P A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Annals of Oncology·2023Open Access
New Oligonucleotide 2′-O-Alkyl N3′→P5′ (Thio)-Phosphoramidates as Potent Antisense Agents: Physicochemical Properties and Biological Activity
Nucleic Acid Therapeutics·2023· 1 cited
DIPG-05. EVALUATION OF TELOMERE-MODIFYING COMPOUND THIO AS A RADIOSENSITIZER AND IMMUNOMODULATOR TO TREAT DIPG
Neuro-Oncology·2023Open Access
Abstract CT050: A phase 2, multi-center, open-label, dose-finding study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC
Cancer Research·2023
Supplementary Figure S2 from Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine
2023Open Access
Supplementary Figure S4 from Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine
2023Open Access
Supplementary Table S1 from Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine
2023Open Access
Supplementary Figure S1 from Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine
2023Open Access
Data from Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine
2023Open Access
Supplementary Figure S2 from Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Jerry W. Shay(11), Woodring E. Wright(9), Krisztina Pongracz(8), Z. Günnur Dikmen(5), Calvin B. Harley(5), Ronald G. Schultz(5), Robert L. Letsinger(5), Brittney‐Shea Herbert(4), Allison C. Chin(4), Erin M. Goldblatt(4), Masood A. Shammas(4), Nikhil C. Munshi(4), Ying Zou(3), Ginelle C. Gellert(3), Mariateresa Fulciniti(3), Shalmica R. Jackson(2), Amelia E. Hochreiter(2), Daria Zielińska(2), Akira Asai(2), Ronald Pruzan(2)